Search Results

23andMe Holding Co. and Nightingale Health Plc announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, released a new genetic Bipolar Disorder report for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition.

Cantargia’s Annual General Meeting on 23 May 2024 resolved in accordance with the following.

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2024 financial results on Tuesday, July 23, 2024, before the market opens.

23andMe Holding Co. presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31-June 4.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster presentations at the 2024 ASCO Annual Meeting, taking place May 31 - June 4 in Chicago.

23andMe Holding Co., a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced that it will report financial results for the fourth quarter and full fiscal year 2024 after the market closes on Thursday, May 23, 2024.

Kane Biotech Inc. will release its first quarter 2024 financial results after market close on Thursday, May 23, 2024.

Biophytis SA, a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, presented the roll-out and results of its phase 2/3 COVA study in the treatment of severe forms of Covid-19 at the 6th edition of the World Congress on Infectious Diseases, held from June 24 to 26, 2024 in Paris, France.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024, which ended March 31, 2024.